2002-064 – Mayo Clinic has patent rights broadly claiming the use of PD-L1 antibodies to treat cancer.
2009-333 – ERB (estrogen receptor beta) mouse monoclonal antibody. Epitope: amino acids 1-140 Known Applications: Enzyme-linked immunosorbent assay (ELISA), Immunohistochemistry (IHC), Western blot (WB) Known Reactivity: Human
2007-110 – Genotype/Phenotype: Mice expressing human MUC1 (mucin) were mated with mice expressing elastase-driven SV40 T antigen. The resulting mice spontaneously develop pancreatic tumors that express high levels of the MUC1. Utility: Useful for investigating immune responses during tumor progression. PMID link: 10975866
2003-128 – Human brain tumors that show invasive behavior in the brains of immunocompromised mice. Numerous, well-characterized tissue grafts are available.
2013-273 – Background: Aerobic fitness is one of the best predictors of all-cause mortality but not easily assessed on a large scale accurately. Technology Description: A web based health fitness assessment tool which may be carried out at any location and requires nothing more than a device camera, web portal, a step, and a chair. Using technology based light reflection and color spectrum, heart... Read More
2013-180 – Snail is a protein that, when it is active induces an invasive phenotype in cancer cells. Inactivation of Snail can occur by phosphorylation of its amino acid residue serine 11 (see attached publication). We have generated a phosphosite specific antibody that targets the protein Snail, when it is phosphorylated at serine 11. This antibody can be utilized as a research tool, but also allows to... Read More
Genetically Engineered Mouse Model of Multiple Myeloma Without IoxP Sites (Vk*MYCwoLoxP) and Transplantable Cell Lines
2013-058 – A transgenic mouse model of multiple myeloma. Vk*MYCwoLoxP mice have conditional MYC activation in germinal center B cells. Mice progress to indolent myeloma with features highly characteristic of human disease. These mice can be used to study the biology and drug treatment of multiple myeloma, and can be crossed with conditional mice strains expressing Cre recombinase. Transplantable... Read More
2013-056 – The invention is a method to prepare hydroxamate resin for use in metal ion separations.
2012-121 – We describe here the establishment of a new WM cell line, MWCL-1. Comprehensive genetic analyses have unequivocally confirmed a clonal relationship between this novel cell line and the founding tumor. MWCL-1 cells exhibit an immunophenotype consistent with a diverse, tumor clone composed of both small B lymphocytes and exhibit an immunophenotype consistent with a diverse, tumor clone... Read More
2012-098 – Agelastatin A (AA) is an anti-neoplastic agent with anti-osteopontin (OPN) activity. Brain tumors often express OPN significantly. A comprehensive chemoinformatic analysis followed by in vivo pharmacokinetic evaluations in mice is performed. CNS penetration of AA is about 10%. AA should be further tested for activity against brain tumors.
2011-271 – We identified a novel translocation of TP63 gene which encodes p63 protein. The translocation leads to overexpression of a dominant negative TP63 isoform. Dominant negative TP63 isoforms lead to inactivation of p53, the most important tumor suppressor known. The translocation can be useful for diagnosis and subclassification of certain peripheral T cell lymphomas, B-cell lymphomas... Read More
2011-184 – Methods and Materials for Assessing Responsiveness PARP Inhibitors and Platinating Agents Methods and materials have been developed for assessing responsiveness to PARP inhibitors and platinating agents by using levels of non-homogous end-joining (NHEI) pathway members to determine if cancer cells that are homologous recombination (hr) - deficient are likely to be susceptible or resistant... Read More
2010-271 – The normal immune system contains T cells bearing antigen receptors which are not readily reactive to self. This invention describes a new method for activating self-reactive T cells in a peptide specific manner, a strategy designed to focus autoimmune cellular responses against cancers and persisting virus infections.
2010-206 – Patient derived tumor tissue samples that have been demonstrated to grow in mice.
2009-362 – Background Topoisomerase I has been used as a drug target for cancer treatment. By inhibiting the religation step of the enzyme, the formation of topo I-DNA complexes block the advancing replication complexes, which will ultimately cause cell death. Thus, measurement of the covalent topo I-DNA complexes can potentially be used to assess therapeutic efficacy of topoisomerase I poisons. ... Read More
2009-219 – Suppressive Monocytes as Markers of Response to Renal Cell Carcinoma Therapy The incidence of and deaths caused by renal cell carcinoma (RCC) are increasing in the United States. Over 80 percent of renal cell carcinomas are due to the subtype clear cell renal cell carcinoma (ccRCC). The majority of patients with renal cell carcinoma confined to the kidney can be cured by surgery; however,... Read More
2008-277 – Anaplastic thyroid carcinoma (ATC) is one of the deadliest cancers with lethality of >99% and survival average of 4 months. Recent publications have demonstrated over 40% of thyroid cell lines are of questionable origin especially ATC cell lines (Schweppe et al., J Clin Endocrinol Metab 2008). We have developed four cell lines from human ATC tumor tissues. These cell lines represent the... Read More
2005-231 – Under the Minnesota Partnership, researchers at the University of Minnesota and at Mayo have developed a database for use in the evaluation of potential prostate cancer biomarkers. Researchers have profiled gene expression of benign and malignant cells that were laser capture microdissected (LCM) from prostate tissues and metastatic adenocarcinomas. In addition, researchers have conducted... Read More
2004-154 – Expression of GALV-fuse gene in tumor cells causes them to fuse with their nontransfected neighbors forming a multicellular syncytia which eventually dies.
2002-039 – Technology Description T cell-mediated immune responses are often harmful in transplant patients and patients with autoimmune disease. Currents treatments to suppress T cell-mediated immune responses include a number of immunosuppressive and anti-inflammatory therapies. A novel means of suppressing this immune response has been developed that utilizes mutant forms of a protein normally... Read More
2001-158 – The Avian Leukosis Virus (AVL) group of retroviruses offers a novel platform for the display of polypeptides and offers novel applications for polypeptide display technology. The ability to display polypeptides on the ALV envelope glycoproteins in a replicating retrovirus with an additional expression cassette presents several unique approaches to use this display platform to probe the... Read More
2001-040 – Using monoclonal antibodies (mAb) to 4-1BB (CD137) T cell molecule, we will be able to show that this treatment can regress established tumors in mouse models in combination with antigenic peptides and cytokine-modified tumor vaccines. Furthermore, treatment by anti-4-1BB mAb also ameliorates experimental autoimmune encephalomyelitis (EAE) in mice, a model of multiple sclerosis in human. ... Read More
1997-112 – An inbred strain of transgenic mice that show tissue-specific expression of the human MUC1 gene. These animals express a form of the human MUC1 gene which codes for the core protein of a mucin expressed by glandular epithelia and carcinomas which develop from these tissues. The core protein is underglycosylated in these cancers and therefore represents a possible target for immunotherapy.... Read More
1997-106 – Mayo researchers have established several human multiple myeloma cell lines, including the ANBL-6, KP-6, KAS-6/1 and DP-6 lines.